Given the feasible and convenient assessment of CEA, the aim of this retrospective study was to investigate whether the kinetic change of CEA levels can be an early indicator for the progression in metastatic NSCLC patients during maintenance therapy with bevacizumab plus pemetrexed. Here, CEACAM5 is linked to non-small cell lung carcinoma.